Vytorin sees growth without nibbling on Zetia

Share this article:

Since launching last year, Schering-Plough's dual-action cholesterol-lowering product Vytorin has risen to sixth among the top nine lipid-lowering drugs, without cannibalizing sales of the firm's blockbuster cholesterol pill, Zetia.
Vytorin's 5 million prescriptions had rung up $496 million in sales as of July, according to IMS Health. And Vytorin has hardly caused a Zetia collapse. As of August, Vytorin had nabbed 7.7 percent of new prescriptions, outpacing Pravachol (pravastatin) at 6.7 percent and Crestor (rosuvastatin) at 5.8 percent.
Zetia holds 7.5 percent of new scripts and, over the same period, has reaped $1.1 billion in sales, IMS Health data show.
Vytorin is a combination of Zetia (ezetimibe) and Merck's Zocor (simvastatin). Simvastatin reduces production of LDL, or "bad cholesterol," in the liver, while Zetia reduces absorption of it in the intestine. Schering-Plough sells Vytorin and Zetia through a partnership with Merck.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.